Stockscreener 앱 받기
68.10
2.79%
1.85
전일 마감가:
$66.25
열려 있는:
$67.28
하루 거래량:
595.32K
Relative Volume:
0.78
시가총액:
$3.42B
수익:
$76.81M
순이익/손실:
$-162.42M
주가수익비율:
-22.78
EPS:
-2.99
순현금흐름:
$-122.49M
1주 성능:
+9.73%
1개월 성능:
+28.98%
6개월 성능:
-19.46%
1년 성능:
+32.65%
1일 변동 폭
$66.44
$68.84
1주일 범위
$61.00
$68.84
52주 변동 폭
$47.86
$107.37
Arcellx Inc Stock (ACLX) Company Profile
명칭
Arcellx Inc
전화
240-327-0603
주소
800 BRIDGE PARKWAY, REDWOOD CITY
ACLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
68.10 | 3.42B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-09-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-03-07 | 개시 | Morgan Stanley | Overweight |
| 2024-01-04 | 재확인 | Needham | Buy |
| 2023-12-19 | 개시 | Scotiabank | Sector Outperform |
| 2023-10-30 | 개시 | TD Cowen | Outperform |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-05-18 | 개시 | Truist | Buy |
| 2023-04-14 | 개시 | Robert W. Baird | Outperform |
| 2023-03-14 | 개시 | Stifel | Buy |
| 2023-02-13 | 개시 | H.C. Wainwright | Buy |
| 2022-12-13 | 재개 | BofA Securities | Buy |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-10-27 | 개시 | Needham | Buy |
| 2022-07-20 | 개시 | Canaccord Genuity | Buy |
| 2022-03-01 | 개시 | BofA Securities | Buy |
| 2022-03-01 | 개시 | SVB Leerink | Outperform |
모두보기
Arcellx Inc 주식(ACLX)의 최신 뉴스
FY2026 EPS Estimates for Arcellx Lifted by Leerink Partnrs - Defense World
Squarepoint Ops LLC Sells 4,670 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx FY2029 EPS Forecast Raised by Leerink Partnrs - Defense World
Top NASDAQ Stocks Arcellx’s Role by Kalkine - Kalkine Media
Two Sigma Advisers LP Acquires 1,100 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Millennium Management LLC Raises Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Ameriprise Financial Inc. Sells 945 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. (NASDAQ:ACLX) Receives Consensus Rating of “Buy” from Brokerages - Defense World
How to Take Advantage of moves in (ACLX) - news.stocktradersdaily.com
Nuveen Asset Management LLC Sells 9,110 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Inc Holds Annual Stockholders Meeting - TipRanks
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - Benzinga
Thinking Of Buying Arcellx Inc (NASDAQ: ACLX) Stock? Here’s What You Need To Know - Stocksregister
Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Business Wire
Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Bluefield Daily Telegraph
Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday - Benzinga
Baron Discovery Fund Initiated a Position in Arcellx (ACLX) - Insider Monkey
BNP Paribas Financial Markets Makes New $1.53 Million Investment in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Inc (ACLX) Receives a Buy from Canaccord Genuity - The Globe and Mail
Mercer Global Advisors Inc. ADV Takes $278,000 Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. Reports Q1 2025 Financial Results - TipRanks
Arcellx Inc’s Anito-cel Shows Promising Results in Phase 2 Trial, Earning Buy Rating from Analyst - TipRanks
Cantor Fitzgerald Expects Reduced Earnings for Arcellx - Defense World
Insiders At Arcellx Sold US$2.6m In Stock, Alluding To Potential Weakness - simplywall.st
Promising Clinical Data and Strong Safety Profile Lead to Buy Rating for Arcellx Inc’s Anito-cel - TipRanks
Arcellx Inc’s Anito-cel Shows Promising Efficacy and Safety in Multiple Myeloma, Earning Buy Rating - TipRanks
Arcellx's Potential Multiple Myeloma Treatment Shows 97% Overall Response Rate in Phase 2 Study; Shares Rise - marketscreener.com
Promising Clinical Trial Results and Safety Profile Support Buy Rating for Arcellx Inc’s Anito-cel Therapy - TipRanks
Arcellx Announces Positive Phase 2 Study Results - TipRanks
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma - BioSpace
Arcellx Reports Positive Data From Phase 2 IMMagine-1 Study - Nasdaq
Arcellx announces data from iMMagine-1 study of anitocabtagene autoleucel - TipRanks
Arcellx, Inc. Announces New Positive Data for Its Immagine-1 Study in Patients with Relapsed And/Or Refractory Multiple Myeloma - marketscreener.com
Arcellx Inc.: Strong Financial Position and Promising Phase 2 Study Outcomes Drive Buy Rating - TipRanks
Here’s Why Arcellx (ACLX) Declined in Q1 - Insider Monkey
Arcellx, Inc. (NASDAQ:ACLX) Receives $109.31 Average Target Price from Brokerages - Defense World
Scotiabank Has Lowered Expectations for Arcellx (NASDAQ:ACLX) Stock Price - Defense World
Piper Sandler Remains a Buy on Arcellx Inc (ACLX) - The Globe and Mail
Arcellx Inc (ACLX) Receives a Buy from Scotiabank - The Globe and Mail
Arcellx First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Needham Sticks to Their Buy Rating for Arcellx Inc (ACLX) - The Globe and Mail
Arcellx (ACLX) Maintains Rating as Price Target is Lowered by Sc - GuruFocus
Arcellx price target lowered to $93 from $133 at Scotiabank - TipRanks
Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates - MSN
Promising Potential of Arcellx Inc’s Anito-cel Therapy: A Buy Rating Backed by Positive Study Data and Strategic Trial Enhancements - TipRanks
Arcellx (ACLX): Scotiabank Adjusts Price Target Amid Regulatory Concerns | ACLX Stock News - GuruFocus
Arcellx’s Promising Trial Results and Strategic Partnerships Justify Buy Rating with $121 Target - TipRanks
Arcellx Inc. Receives Buy Rating: Strong Financial Outlook and Promising Data Catalysts - TipRanks
Promising Potential of Arcellx Inc’s Anito-cel Program Drives Buy Rating - TipRanks
ARCELLX Earnings Results: $ACLX Reports Quarterly Earnings - Nasdaq
Earnings Flash (ACLX) ARCELLX INC. Reports Q1 Revenue $8.1M, vs. FactSet Est of $19.5M - marketscreener.com
Arcellx Inc (ACLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
1.51%
자본화:
|
볼륨(24시간):